tetrahydrogestrinone (THG)
... periods up to 12 days in direct comparison to testosterone propionate (o.1mg/animal/day s. c.): THG induced (a dose dependent) androgenic effect on prostate and vesicular seminales parameters and LH serum levels in doses of 1,3,10mg/animal. This androgenic stimulation could be antagonized by the sim ...
... periods up to 12 days in direct comparison to testosterone propionate (o.1mg/animal/day s. c.): THG induced (a dose dependent) androgenic effect on prostate and vesicular seminales parameters and LH serum levels in doses of 1,3,10mg/animal. This androgenic stimulation could be antagonized by the sim ...
6 - cazacu - safety.indd
... referring to drug safety and emphasized after the tragedy with thalidomide. Collecting spontaneous reported adverse events which occur during pregnancy and after may help decide if a drug can affect the unborn or the mother, in which manner, and to establish the risk-benefit balance. The spontaneous ...
... referring to drug safety and emphasized after the tragedy with thalidomide. Collecting spontaneous reported adverse events which occur during pregnancy and after may help decide if a drug can affect the unborn or the mother, in which manner, and to establish the risk-benefit balance. The spontaneous ...
cmc chapter 22
... Organic Compounds Containing the Carbonyl Group (cont.) • A ketone is an organic compound in which the carbon of the carbonyl group is bonded to two other carbon atoms. • Ketones are named by changing the –e at the end of the alkane name to –one, and including a number before the name to indicate t ...
... Organic Compounds Containing the Carbonyl Group (cont.) • A ketone is an organic compound in which the carbon of the carbonyl group is bonded to two other carbon atoms. • Ketones are named by changing the –e at the end of the alkane name to –one, and including a number before the name to indicate t ...
Potential Herb-Drug Interactions for Commonly
... information in the Potential Interaction column. For example, clinical studies found that administration of St John’s wort resulted in decreased levels of cancer chemotherapeutic drugs. (Italicized words represent the information in the Herb-Drug Interaction chart below.) More details may be provide ...
... information in the Potential Interaction column. For example, clinical studies found that administration of St John’s wort resulted in decreased levels of cancer chemotherapeutic drugs. (Italicized words represent the information in the Herb-Drug Interaction chart below.) More details may be provide ...
Sustainable production of industrial chemicals from
... fuel price fluctuations, and minimize greenhouse gas emissions. However, fuels are very large-volume, low value, single-use commodity products. Once fuels are combusted, they are converted to products (e.g., CO, CO2, and H2O) that are emitted into the atmosphere. Accordingly, fuels typically are sol ...
... fuel price fluctuations, and minimize greenhouse gas emissions. However, fuels are very large-volume, low value, single-use commodity products. Once fuels are combusted, they are converted to products (e.g., CO, CO2, and H2O) that are emitted into the atmosphere. Accordingly, fuels typically are sol ...
Innovation Track: Pharmacogenomics
... enzymes such as the cytochrome P450 isozyme P450 2D6. Such individuals are referred to as "poor metabolizers" of drugs such as debrisoquin, dextromethorphan, the tricyclic antidepressants, and clozapine. These individuals may develop higher than expected plasma concentrations of clozapine when given ...
... enzymes such as the cytochrome P450 isozyme P450 2D6. Such individuals are referred to as "poor metabolizers" of drugs such as debrisoquin, dextromethorphan, the tricyclic antidepressants, and clozapine. These individuals may develop higher than expected plasma concentrations of clozapine when given ...
Important Information for Patients (Please read before treatment
... If you have AMD you may be suitable for treatment with a drug containing antivascular endothelial growth factor (anti-VEGF). This kind of drug slows the development of new blood vessels and in many cases can stop the disease. Some patients have even reported improved vision. Two anti-VEGF drugs are ...
... If you have AMD you may be suitable for treatment with a drug containing antivascular endothelial growth factor (anti-VEGF). This kind of drug slows the development of new blood vessels and in many cases can stop the disease. Some patients have even reported improved vision. Two anti-VEGF drugs are ...
20808 AlleRx PE.indd
... Drug Interactions: Monoamine oxidase (MAO) inhibitors and beta-adrenergic blockers increase the effects of sympathomimetic amines. Sympathomimetic amines may reduce the antihypertensive effects of methyldopa, guanethidine, mecamylamine, reserpine and veratrum alkaloids. Additive anticholinergic effe ...
... Drug Interactions: Monoamine oxidase (MAO) inhibitors and beta-adrenergic blockers increase the effects of sympathomimetic amines. Sympathomimetic amines may reduce the antihypertensive effects of methyldopa, guanethidine, mecamylamine, reserpine and veratrum alkaloids. Additive anticholinergic effe ...
CHB_Prescribe_012_ EPR clinical checking and supply requests
... dispensed. If a different amount is required, indicate here by using the drop down menu, or in the additional information box. o Priority - the item(s) will appear at the top of all work-lists Use this option when ordering items for TTO, critical medicine e.t.c Only use this option if really necessa ...
... dispensed. If a different amount is required, indicate here by using the drop down menu, or in the additional information box. o Priority - the item(s) will appear at the top of all work-lists Use this option when ordering items for TTO, critical medicine e.t.c Only use this option if really necessa ...
Chapter 26 – The Biomanufacturing of Biotechnology Products
... a vaccine, a tissue, or various proteins such as cytokines, enzymes, fusion proteins, whole cells, and viral and nonviral gene therapies. Biologic products are derived from living systems that may or may not be altered. Recombinant DNA technology has produced many biological products and has allowed ...
... a vaccine, a tissue, or various proteins such as cytokines, enzymes, fusion proteins, whole cells, and viral and nonviral gene therapies. Biologic products are derived from living systems that may or may not be altered. Recombinant DNA technology has produced many biological products and has allowed ...
Responding to an Opiate Overdose
... 4. Screw the nasal atomizer onto the tip of the syringe. The naloxone is now ready to use. 5. Place the assembled naloxone atomizer in one of the overdose victim’s nostrils. 6. Press firmly on the base of the glass vial or plunger, spraying half of the naloxone deep into the overdose victim’s nasal ...
... 4. Screw the nasal atomizer onto the tip of the syringe. The naloxone is now ready to use. 5. Place the assembled naloxone atomizer in one of the overdose victim’s nostrils. 6. Press firmly on the base of the glass vial or plunger, spraying half of the naloxone deep into the overdose victim’s nasal ...
PDF/153KB - Sumitomo Dainippon Pharma
... anti-apoptotic gene, may be responsible for the potential clinical anti-cancer activity observed with alvocidib. Alvocidib is an investigational intravenous small-molecule agent and it received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EM ...
... anti-apoptotic gene, may be responsible for the potential clinical anti-cancer activity observed with alvocidib. Alvocidib is an investigational intravenous small-molecule agent and it received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EM ...
Placental structure, function and drug transfer
... drugs including digoxin, dexamethasone, cyclosporin A, and chemotherapeutic agents like vincristine and vinblastine), and the multidrug resistance proteins 1– 3 (involved in the transfer of drugs such as methotrexate and HIV protease inhibitors).8,11 The expression and distribution of drug transport ...
... drugs including digoxin, dexamethasone, cyclosporin A, and chemotherapeutic agents like vincristine and vinblastine), and the multidrug resistance proteins 1– 3 (involved in the transfer of drugs such as methotrexate and HIV protease inhibitors).8,11 The expression and distribution of drug transport ...
Chemistry - Tumkur University
... Recapitulation of s- and p-Block Elements Periodicity in s- and p-block elements with respect to electronic configuration, atomic and ionic size, ionization enthalpy, electronegativity (Pauling, Mulliken, and Alfred-Rochow scales).Allotropy in C, S, and P. Inert pair effect, diagonal relationship an ...
... Recapitulation of s- and p-Block Elements Periodicity in s- and p-block elements with respect to electronic configuration, atomic and ionic size, ionization enthalpy, electronegativity (Pauling, Mulliken, and Alfred-Rochow scales).Allotropy in C, S, and P. Inert pair effect, diagonal relationship an ...
MACROLIDES Macrolide antibiotics contain a many membered
... • Inhibits cell wall synthesis (2nd stage of cell wall synthesis). • Binds with high affinity to the D-alanyl-Dalanine terminus of cell wall precursor units, at the crucial site of attachment and thereby inhibits vital peptidoglycan polymerase and ...
... • Inhibits cell wall synthesis (2nd stage of cell wall synthesis). • Binds with high affinity to the D-alanyl-Dalanine terminus of cell wall precursor units, at the crucial site of attachment and thereby inhibits vital peptidoglycan polymerase and ...
About the Naplex
... Concentrate your efforts on important areas (THINK TOP 200---Chapter 8) http://www.studystack.com/ ---click on medicine Practice under actual exam conditions Read each question carefully (cover the answers) ...
... Concentrate your efforts on important areas (THINK TOP 200---Chapter 8) http://www.studystack.com/ ---click on medicine Practice under actual exam conditions Read each question carefully (cover the answers) ...
Module 2. Clinical Pharmacy in gastroenterology, hepatology
... 18. Which of the following agents is a general tone-increasing drug of plant origin? A. Meridil B. * Eleuterococci’s extract C. Pantocrin D. Caffeine E. T-activin 19. Indicate a general tone-increasing drug, which is an agent of animal origin? A. * Pantocrin B. Amphetamine C. Sydnocarb D. Camphor E. ...
... 18. Which of the following agents is a general tone-increasing drug of plant origin? A. Meridil B. * Eleuterococci’s extract C. Pantocrin D. Caffeine E. T-activin 19. Indicate a general tone-increasing drug, which is an agent of animal origin? A. * Pantocrin B. Amphetamine C. Sydnocarb D. Camphor E. ...
Amphetamine-Type Stimulants in Latin America
... In Latin America, cannabis, cocaine and their derivatives continue to be the most significant drug problems both in terms of use and in terms of trafficking. However, although still low, especially when compared to other regions of the world like Asia, use of amphetamine-type stimulants seems to be ...
... In Latin America, cannabis, cocaine and their derivatives continue to be the most significant drug problems both in terms of use and in terms of trafficking. However, although still low, especially when compared to other regions of the world like Asia, use of amphetamine-type stimulants seems to be ...
anticoagulant
... Treatment of HIT • Discontinue all heparin • If need to continue anti-coagulation, use danaparoid (orgaran). • Avoid platelet transfusions • Thrombosis: use danaparoid or thrombin inhibitor(Hirudin) ...
... Treatment of HIT • Discontinue all heparin • If need to continue anti-coagulation, use danaparoid (orgaran). • Avoid platelet transfusions • Thrombosis: use danaparoid or thrombin inhibitor(Hirudin) ...
Saw Palmetto Botany
... • If used as an anthelminthic, the patients should be monitored to ensure efficacy. • Caution should be taken to monitor urine output. As with any diuretic, forced diuresis with urinary obstruction may cause nephrotoxicity. ...
... • If used as an anthelminthic, the patients should be monitored to ensure efficacy. • Caution should be taken to monitor urine output. As with any diuretic, forced diuresis with urinary obstruction may cause nephrotoxicity. ...
AL Chemistry Group Project (TAS)
... Gefitinib binds to the adenosine triphosphate (ATP)-binding site of the enzyme, initiates a signal that can influence many aspects of tumor cell biology including growth, survival, metastasis, and angiogenesis, as well as tumor cell sensitivity to chemotherapy and radiation therapy. ...
... Gefitinib binds to the adenosine triphosphate (ATP)-binding site of the enzyme, initiates a signal that can influence many aspects of tumor cell biology including growth, survival, metastasis, and angiogenesis, as well as tumor cell sensitivity to chemotherapy and radiation therapy. ...
Guidelines for the Management of Adverse Drug
... periods. Hepatotoxicity has not been reported with extensive use of lower doses (15-30mg/kg/d) in short course regimens.2 ...
... periods. Hepatotoxicity has not been reported with extensive use of lower doses (15-30mg/kg/d) in short course regimens.2 ...
Strategies for Companion Diagnostic Development in a
... Targeted Therapeutics Drug therapy directed towards a specific patient population as identified by a diagnostic (e.g. Herceptin, Gleevec) ...
... Targeted Therapeutics Drug therapy directed towards a specific patient population as identified by a diagnostic (e.g. Herceptin, Gleevec) ...
preclinical evaluation of central nervous system stimulant agents
... hyperactivity disorder (ADHD), a condition in which people have unusually high activity levels and short attention spans. People with this condition are easily distracted and may have trouble sitting still, planning ahead, or finishing what they start. Central nervous system stimulants increase atte ...
... hyperactivity disorder (ADHD), a condition in which people have unusually high activity levels and short attention spans. People with this condition are easily distracted and may have trouble sitting still, planning ahead, or finishing what they start. Central nervous system stimulants increase atte ...
Drug discovery
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered through identifying the active ingredient from traditional remedies or by serendipitous discovery. Later chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that have a desirable therapeutic effect in a process known as classical pharmacology. Since sequencing of the human genome which allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compounds libraries against isolated biological targets which are hypothesized to be disease modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy.Modern drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, it will begin the process of drug development prior to clinical trials. One or more of these steps may, but not necessarily, involve computer-aided drug design. Modern drug discovery is thus usually a capital-intensive process that involves large investments by pharmaceutical industry corporations as well as national governments (who provide grants and loan guarantees). Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, ""expensive, difficult, and inefficient process"" with low rate of new therapeutic discovery. In 2010, the research and development cost of each new molecular entity (NME) was approximately US$1.8 billion. Drug discovery is done by pharmaceutical companies, with research assistance from universities. The ""final product"" of drug discovery is a patent on the potential drug. The drug requires very expensive Phase I, II and III clinical trials, and most of them fail. Small companies have a critical role, often then selling the rights to larger companies that have the resources to run the clinical trials.Discovering drugs that may be a commercial success, or a public health success, involves a complex interaction between investors, industry, academia, patent laws, regulatory exclusivity, marketing and the need to balance secrecy with communication. Meanwhile, for disorders whose rarity means that no large commercial success or public health effect can be expected, the orphan drug funding process ensures that people who experience those disorders can have some hope of pharmacotherapeutic advances.